RCRI

The Revised Cardiac Risk Index (RCRI) is a well-established tool used to predict the risk of cardiac complications in patients undergoing non-cardiac surgery. The RCRI takes into account several preoperative risk factors that are associated with adverse cardiac outcomes. These factors include:

High-risk type of surgery

History of ischemic heart disease

History of congestive heart failure

History of cerebrovascular disease

Preoperative treatment with insulin

Preoperative serum creatinine > 2.0 mg/dL

To use the RCRI in non-cardiac surgery, you would assess each patient for these six risk factors prior to the surgical procedure. Each risk factor is given a point value, which is added together to give a total score. The higher the score, the greater the risk of cardiac complications. The total score can be used to guide decision-making regarding preoperative testing, optimization of medical therapy, and the need for postoperative cardiac monitoring.

The following is a breakdown of the RCRI scoring system:

High-risk surgery: 1 point

History of ischemic heart disease: 1 point

History of congestive heart failure: 1 point

History of cerebrovascular disease: 1 point

Preoperative treatment with insulin: 1 point

Preoperative serum creatinine > 2.0 mg/dL: 1 point

Patients with a score of 0 are considered low risk, with a 0.4% risk of major cardiac events. A score of 1 or 2 indicates an intermediate risk, with a 1.0% and 7.6% risk of major cardiac events, respectively. Patients with a score of 3 or higher are considered high risk, with a 11% risk of major cardiac events.

In summary, the RCRI is a useful tool for predicting the risk of cardiac complications in patients undergoing non-cardiac surgery. By assessing a patient's preoperative risk factors and calculating their RCRI score, clinicians can identify patients at higher risk of cardiac events and take appropriate measures to optimize their care.

acute myocardium infaction

The use of dual antiplatelet therapy, statins, and heparin in the management of acute myocardial infarction is supported by the guidelines of the American College of Cardiology (ACC). These medications are used to stabilize the atherosclerotic plaque, prevent further thrombus formation, and reduce the risk of recurrent cardiovascular events.

Dual antiplatelet therapy involves the use of two different medications that act on platelets, which are the cells in the blood that are involved in clot formation. The two medications typically used are aspirin and a P2Y12 inhibitor, such as clopidogrel, ticagrelor, or prasugrel. Aspirin works by inhibiting the production of thromboxane A2, a molecule that promotes platelet aggregation and vasoconstriction. P2Y12 inhibitors block the activation of platelets by adenosine diphosphate (ADP), which is released from activated platelets and promotes further platelet aggregation. By inhibiting platelet activation and aggregation, dual antiplatelet therapy reduces the risk of recurrent thrombotic events in patients with acute myocardial infarction.

Statins are a class of medications that lower cholesterol levels in the blood. They work by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. In addition to their cholesterol-lowering effects, statins also have pleiotropic effects that are thought to contribute to their cardiovascular benefits. For example, statins can reduce inflammation in the arterial wall, stabilize atherosclerotic plaques, and improve endothelial function, which is the ability of blood vessels to dilate and constrict in response to various stimuli. These effects are thought to reduce the risk of recurrent cardiovascular events in patients with acute myocardial infarction.

Heparin is an anticoagulant medication that works by enhancing the activity of antithrombin III, a natural inhibitor of coagulation. By inhibiting the formation of blood clots, heparin reduces the risk of further thrombus formation in patients with acute myocardial infarction. Heparin is typically administered intravenously in the acute setting and is often followed by the use of an oral anticoagulant, such as warfarin or a direct oral anticoagulant (DOAC), for long-term management.

Overall, the use of dual antiplatelet therapy, statins, and heparin in the management of acute myocardial infarction is supported by strong evidence from clinical trials and is recommended by the ACC guidelines to reduce the risk of recurrent cardiovascular events in these patients.

PAH AS PER ECHOCARDIOGRAPHIC EVALUATION

Based on Feigenbaum's textbook on echocardiography, the assessment of right ventricular (RV) pressure using echocardiography can be classified as follows:

Normal RV pressure: A normal RV systolic pressure is less than or equal to 30 mmHg.

Mildly elevated RV pressure: A mildly elevated RV systolic pressure is between 30 and 40 mmHg.

Moderately elevated RV pressure: A moderately elevated RV systolic pressure is between 40 and 70 mmHg.

Severely elevated RV pressure: A severely elevated RV systolic pressure is greater than 70 mmHg.

It is important to note that the assessment of RV pressure using echocardiography is based on the estimation of the tricuspid regurgitation (TR) jet velocity, which is then used to calculate the RV systolic pressure using the modified Bernoulli equation. However, the estimation of RV pressure using echocardiography is not always accurate and may be influenced by several factors, including technical limitations and underlying pulmonary and cardiac diseases. Therefore, the echocardiographic assessment of RV pressure should be interpreted in the context of the clinical history and physical examination findings.

echocardiographic evaluation

A 2D echocardiogram (also known as a transthoracic echocardiogram) is a non-invasive imaging technique that uses ultrasound waves to visualize the structure and function of the heart. An ideal normal 2D echocardiographic report format should include the following components:

Patient Information: Patient's name, age, sex, and medical record number.

Study Quality: Indicate the image quality and the equipment used for the study.

Left Ventricle (LV) Evaluation:

LV Dimensions: Report LV dimensions at end-diastole (LVEDD) and end-systole (LVESD).

LV Wall Thickness: Report the thickness of the interventricular septum (IVS) and the posterior wall (PW) in end-diastole.

LV Function: Evaluate LV systolic function by reporting ejection fraction (EF) and wall motion abnormalities.

Right Ventricle (RV) Evaluation:

RV Dimensions: Report RV dimensions at end-diastole (RVEDD) and end-systole (RVESD).

RV Function: Evaluate RV systolic function by reporting fractional area change (FAC), tricuspid annular plane systolic excursion (TAPSE), and RV wall motion abnormalities.

Atrial Evaluation:

Left Atrium (LA): Report the dimensions of LA and presence of LA thrombus or spontaneous echo contrast.

Right Atrium (RA): Report the dimensions of RA.

Valve Evaluation:

Mitral Valve: Report mitral valve area (MVA) by planimetry or pressure half-time, presence of mitral valve regurgitation (MR), and description of any mitral valve leaflet or chordal abnormalities.

Aortic Valve: Report aortic valve area (AVA) by continuity equation or planimetry, presence of aortic valve regurgitation (AR), and description of any aortic valve leaflet or root abnormalities.

Tricuspid Valve: Report presence of tricuspid valve regurgitation (TR) and description of any tricuspid valve leaflet or chordal abnormalities.

Pulmonic Valve: Report presence of pulmonic valve regurgitation (PR) and description of any pulmonic valve leaflet or root abnormalities.

Pericardium and Other Findings:

Report any pericardial effusion or other relevant findings.

Conclusion:

Provide a summary of findings, including normal or abnormal measurements and any specific abnormalities found.

Indicate the need for further evaluation or management, if necessary.

Interpretation: The report should be interpreted by a qualified cardiologist or cardiac sonographer, and a final interpretation should be included in the report.

Adenosine and SVT

Adenosine is a medication commonly used for the treatment of supraventricular tachycardia (SVT), which is a rapid heart rhythm originating from the upper chambers of the heart. Adenosine is classified as an antiarrhythmic agent, and it works by slowing down the electrical conduction in the heart, which helps to terminate the SVT.

The mechanism of action of adenosine is based on its ability to activate specific receptors called adenosine receptors, which are present in various tissues, including the heart. In the heart, adenosine activates adenosine receptors on the surface of cardiac cells, leading to an inhibition of the electrical conduction through the atrioventricular (AV) node, the structure responsible for regulating the communication between the atria and the ventricles.

The AHA (American Heart Association) guidelines recommend adenosine as the first-line treatment for the acute termination of regular narrow-complex SVT in both stable and unstable patients. The recommended dose of adenosine is 6 mg given rapidly by intravenous (IV) bolus, followed by a saline flush, and then increased to 12 mg if the first dose is ineffective. In cases of unstable patients, immediate cardioversion may be considered.

The effectiveness of adenosine in terminating SVT has been demonstrated in several studies. For example, a randomized controlled trial published in the New England Journal of Medicine showed that adenosine was effective in terminating 91% of SVT episodes, with a mean time to termination of 16 seconds.

In summary, adenosine is used in SVT due to its ability to inhibit the electrical conduction through the AV node, leading to the termination of the arrhythmia. Its effectiveness has been well established in numerous clinical studies, and it is recommended as the first-line treatment in the AHA guidelines for the acute termination of regular narrow-complex SVT.

APTT

The desired APTT value for a patient receiving heparin therapy depends on the indication for heparin therapy and the specific guidelines of the institution or healthcare provider. Generally, the therapeutic range for APTT in patients receiving heparin therapy is 1.5 to 2.5 times the control value, as determined by the laboratory.

The American College of Cardiology (ACC) provides guidelines for heparin therapy in the treatment of acute coronary syndrome (ACS) and deep vein thrombosis (DVT). For ACS, the recommended target APTT range is 50-70 seconds. For DVT, the recommended target APTT range is 1.5-2.5 times the control value. However, it is important to note that the specific target APTT range may vary depending on the individual patient's medical history, comorbidities, and other factors, and should be determined by the healthcare provider.

It is also worth noting that while APTT is a useful test for monitoring heparin therapy, other factors, such as the patient's clinical response to therapy and the results of other laboratory tests, should be considered when determining the appropriate heparin dosage and monitoring the patient's anticoagulation status.

noac

individual NOAC, including their pros and cons:

Dabigatran (Pradaxa):

Pros:

Twice-daily dosing regimen, which may be preferable for patients who prefer a medication schedule that aligns with meals or bedtime.

Low potential for drug interactions.

Reversal agent (idarucizumab) available in case of bleeding or urgent surgery.

Cons:

Higher rate of gastrointestinal adverse events compared to other NOACs.

May require dose adjustments in patients with renal impairment.

Higher cost compared to other NOACs.

Rivaroxaban (Xarelto):

Pros:

Once-daily dosing regimen, which may be more convenient for some patients.

Low potential for food interactions.

Reversal agent (andexanet alfa) available in case of bleeding or urgent surgery.

Cons:

Higher risk of gastrointestinal bleeding compared to other NOACs.

May require dose adjustments in patients with renal impairment.

May interact with some medications, including strong CYP3A4 inhibitors.

Apixaban (Eliquis):

Pros:

Twice-daily dosing regimen, which may be preferable for patients who prefer a medication schedule that aligns with meals or bedtime.

Lowest rate of major bleeding compared to other NOACs.

May have a lower risk of gastrointestinal bleeding compared to other NOACs.

Cons:

May require dose adjustments in patients with renal impairment.

Higher cost compared to some other NOACs.

No specific reversal agent available, but reversal strategies are being developed.

Edoxaban (Savaysa/Lixiana):

Pros:

Once-daily dosing regimen, which may be more convenient for some patients.

Low potential for drug interactions.

May have a lower risk of gastrointestinal bleeding compared to other NOACs.

Cons:

May require dose adjustments in patients with renal impairment.

Higher risk of bleeding in patients with a body weight of less than 60 kg.

No specific reversal agent available, but reversal strategies are being developed.

In summary, each NOAC has its own set of pros and cons, and the choice of which NOAC to use should be individualized based on patient preference, clinical factors, and cost. While all NOACs have a lower risk of bleeding compared to warfarin, they do carry a risk of bleeding, and physicians should be familiar with the management of bleeding events in patients taking these medications. It is important to discuss the benefits and risks of each NOAC with patients to help them make an informed decision.